Heron Therapeutics, Inc. (HRTX) Stock

Heron Therapeutics, Inc. operates as a leading biotechnology company dedicated to developing innovative treatments that address critical unmet needs in patient care. At the forefront of its offerings is a proprietary drug delivery technology known as Biochronomer, designed to administer therapeutic levels of various short-acting pharmacological agents over extended periods with a single dose. This innovation underpins the company's diverse portfolio of product candidates.

Among its flagship offerings is SUSTOL (granisetron), an extended-release injection aimed at preventing acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy. Additionally, Heron Therapeutics, Inc. provides CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist used for managing nausea and vomiting linked to highly emetogenic cancer chemotherapy, as well as moderately emetogenic regimens.

The company continues to advance its pipeline with ZYNRELEF, a dual-acting local anesthetic combining bupivacaine and a low dose of meloxicam, designed to provide effective pain relief. Further expanding its therapeutic reach, Heron Therapeutics, Inc. is developing HTX-019 for the prevention of postoperative nausea and vomiting, alongside HTX-034 for managing postoperative pain. These initiatives are underscored by ongoing Phase Ib/II clinical studies, including those evaluating HTX-034's efficacy in patients undergoing bunionectomy.

Founded in 1983 and headquartered in San Diego, California, Heron Therapeutics, Inc. was initially established as A.P. Pharma, Inc., later rebranding in January 2014 to reflect its evolving focus and commitment to pioneering advancements in pharmaceutical solutions. The company's dedication to innovation and patient-centric research continues to drive its efforts in transforming treatment outcomes across therapeutic areas.